Abattis Bioceuticals Corp. engages in the aggregation, integration, and investment in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2011-04-09. The firm aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. The company operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. The company offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. The company is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue
1,524
1,524
1,666
1,832
1,947
2,025
Revenue Growth (YoY)
-9%
-9%
-9%
-6%
-4%
22%
Cost of Revenue
1,024
1,024
1,110
1,234
1,395
1,410
Gross Profit
500
500
555
598
552
614
Selling, General & Admin
346
324
342
367
386
406
Research & Development
--
22
23
25
--
--
Operating Expenses
392
392
410
436
409
456
Other Non Operating Income (Expenses)
-6
-6
-6
-11
17
4
Pretax Income
49
49
-87
-13
14
111
Income Tax Expense
7
7
14
8
28
9
Net Income
41
41
-101
-21
-13
101
Net Income Growth
-141%
-141%
381%
62%
-112.99%
63%
Shares Outstanding (Diluted)
94.3
94
95.6
95.3
95.3
97.1
Shares Change (YoY)
1%
-2%
0%
0%
-2%
1%
EPS (Diluted)
0.44
0.43
-1.06
-0.22
-0.14
1.05
EPS Growth
-141%
-141%
365%
63%
-112.99%
62%
Free Cash Flow
50
50
132
114
61
138
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
32.8%
32.8%
33.31%
32.64%
28.35%
30.32%
Operating Margin
7.02%
7.02%
8.7%
8.78%
7.34%
7.8%
Profit Margin
2.69%
2.69%
-6.06%
-1.14%
-0.66%
4.98%
Free Cash Flow Margin
3.28%
3.28%
7.92%
6.22%
3.13%
6.81%
EBITDA
179
179
218
237
222
243
EBITDA Margin
11.74%
11.74%
13.08%
12.93%
11.4%
12%
D&A For EBITDA
72
72
73
76
79
85
EBIT
107
107
145
161
143
158
EBIT Margin
7.02%
7.02%
8.7%
8.78%
7.34%
7.8%
Effective Tax Rate
14.28%
14.28%
-16.09%
-61.53%
200%
8.1%
Follow-Up Questions
What are Abattis Bioceuticals Corp's key financial statements?
According to the latest financial statement (Form-10K), ACCO Brands Corp has a total asset of $2,253, Net profit of $41
What are the key financial ratios for ATTBF?
ACCO Brands Corp's Current ratio is 1.41, has a Net margin is 2.69, sales per share of $16.21.
How is Abattis Bioceuticals Corp's revenue broken down by segment or geography?
ACCO Brands Corp largest revenue segment is ACCO Brands Americas, at a revenue of 999,900,000 in the most earnings release.For geography, United States is the primary market for ACCO Brands Corp, at a revenue of 719,700,000.
Is Abattis Bioceuticals Corp profitable?
yes, according to the latest financial statements, ACCO Brands Corp has a net profit of $41
Does Abattis Bioceuticals Corp have any liabilities?
yes, ACCO Brands Corp has liability of 1,588
How many outstanding shares for Abattis Bioceuticals Corp?
ACCO Brands Corp has a total outstanding shares of 90.13